Results From the Phase 1 Dose Escalation Study of XMT-1592, a NaPi2b-Directed Dolasynthen **Antibody-Drug Conjugate (ADC)**



Erika P. Hamilton¹; Kyriakos P. Papadopoulos²; Minal A. Barve³; Nehal J. Lakhani⁴; Timothy F. Burns⁵; Robert A. Burger⁶; Adi Reske⁶; Kelley Wekheye⁶; Anthony Tolcher⁷

¹Sarah Cannon Research Institute, Nashville, TN, United States; ²START San Antonio, TX, United States; ³Mary Crowley Cancer Research Center, Dallas, TX, United States; ¹Sarah Cannon Research Center, Dallas, TX, United States; ¹Sarah Center, Dallas, Dal ⁴START Midwest, Grand Rapids, MI, United States; ⁵University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, United States; ⁶Mersana Therapeutics Inc, Cambridge, MA, United States; ⁷Next Oncology, San Antonio, TX, United States

INTRODUCTION

- ADCs have provided substantial benefits to patients; nonetheless, observed platform toxicities and payload resistance limit their use
- NaPi2b is a sodium-dependent phosphate transporter broadly expressed in ovarian cancer (OC), non-small cell lung cancer (NSCLC) and in healthy Type II pneumocytes in the lung, but with limited expression in other healthy tissue (Table 1)¹
- ADCs targeting NaPi2b have demonstrated clinical activity in platinum-resistant OC, but have been associated with both target-related toxicities (ILD/pneumonitis) and platform-related toxicities, including AST increase, thrombocytopenia/platelet count decrease (observed with XMT-1536)², and neutropenia and neuropathy (observed with lifatuzumab vedotin)³
- Dolasynthen is a next-generation platform designed to produce homogeneous ADCs with precise control of the drug-to-antibody ratio and site-specific bioconjugation with the goal of improving efficacy and reducing platform-related toxicities⁴
- Improvements in PK, in vivo efficacy and tolerability were observed preclinically with XMT-1592 when compared with an earlier NaPi2b-targeted ADC, XMT-1536 (UpRi; data on file)

RESULTS (Data cutoff: November 1, 2022)

Patient Demographics and Disease **Characteristics**

Safety analysis set (N=31)	
Median age (range), years	68 (47-82)
ECOG PS, n (%)	
0	4 (12.9)
1	27 (87.1)

Safety - TRAEs in ≥15% of Patients



• Here we report Phase 1 dose escalation data for XMT-1592, a Dolasynthen NaPi2b-directed ADC in patients with OC and NSCLC

NaPi2b Highly Expressed in Normal Lung and Ovarian Cancer Tissues¹

Type of ticcue	IHC Score ^a			
Type of tissue	0	1	2	3
Normal breast (n=4)	0	0	1	3
Breast cancer (n=10)	8	2	0	0
Normal lung (n=9)	0	0	1	8
Lung cancer (n=11)	5	5	0	1
Normal uterus (n=3)	0	0	1	2
Normal oviduct (n=2)	0	0	0	2
Normal ovary (n=5)	5	0	0	0
Ovarian cancer (n=10)	0	1	1	8

Table 1: Semi-Quantitative Scoring of IHC Staining for NaPi2b (MX35) in a Panel of Normal and Cancer Tissues

• NaPi2b is highly expressed in normal lung tissue at a cumulative IHC score comparable to that for OCs¹

Type II pneumocytes in the lungs may be proliferating and thus susceptible to a microtubule inhibitor

Leveraging Learnings to Develop an Improved Cytotoxic ADC Platform

Dolaflexin (First-generation cytotoxic ADC platform)

 AF-HPA payload with controlled bystander effect; highly potent anti-tubulin inhibitor selectively toxic to rapidly dividing cells designed to avoid dose-limiting neuropathy or neutropenia

Goals for Next-Generation Platform

 DAR customization for target • Antibody-like PK

Enhance tumor payload delivery



 AF-HPA payload with controlled bystander effect; highly potent anti-tubulin inhibitor selectively toxic to rapidly dividing cells designed to avoid dose-limiting neuropathy or

3x greater

tumor delivery

DAR ~15.9

- Vehicle

Primary tumor type, n (%) NSCLC ^b OC	3 (9.7) 28 (90.3)	A
Prior lines of therapy, n (%) 1-3 ≥4	13 (41.9) 18 (58.1)	H
Prior therapy, n (%) Bevacizumab PARP inhibitor	16 (51.6) 18 (58.1)	C
Platinum-free interval, n (%) 0-3 Months >3-6 Months >6 Months Unknown	11 (35.5) 9 (29.0) 7 (22.6) 4 (12.9)	1(
NaPi2b H-score, n (%) Determined High (H-score ≥110) Low (H-score <110) Not determined	25 (80.6) 12 (48) 13 (52) 6 (19.4)	•

- Pneumonitis observed (including 1 G5) likely an on-target toxicity based on NaPi2b expression in Type II pneumocytes
- No severe peripheral neuropathy, neutropenia, or ocular toxicity
- No thrombocytopenia or treatment-related bleeding events
- XMT-1592 half-life: 7.5-10.3 days

Platform Toxicities Appear to be Greatly Reduced with Next-Generation **Dolasynthen Platform**^c

		First-Generation XMT-1536 (N=268) ^d 36 mg/m ² n (%)		Next-Generation XMT-1592 (N=31) All DLs n (%)	
	TRAEs				
		All grades	Grade ≥3	All grades	Grade ≥3
Presumed off-target	AST elevation, n (%)	185 (69.0)	124 (46.3)	3 (9.7)	0
	Platelet count decrease/ thrombocytopenia, n (%)	133 (49.6)	32 (11.9)	0	0
platform toxicities	Nausea, n (%)	139 (51.9)	6 (2.2)	10 (32.3)	0
	Fatigue, n (%)	118 (44.0)	26 (9.7)	10 (32.3)	0
Presumed on-target toxicity	Pneumonitis, n (%)	26 (9.7)	2 (<1)	12 (38.7)	3 (9.7)

Table 2: Comparison table between XMT-1536 and XMT-1592 Based on two independent studies; select AEs

• Observed pneumonitis believed to be due to target-dependent uptake of the ADC by the Type II pneumocytes in the lungs expressing NaPi2b

•	Stochastic (random) bioconjugation	haraaa officeou	neutropenia
•	Heterogeneous DAR ~10	Increase enicacy	 Site-specific conjugation
•	Fully preserved Fcy receptor interaction: could	 Reduce platform toxicity 	 Homogeneous DAR 6
	lead to non-target uptake	 Expand therapeutic index 	• Significantly reduced Fcγ binding

Preclinical Studies: Dolasynthen Outperforms Dolaflexin at Equal Payload Doses

• Dolasynthen platform enables the creation of single-species ADCs that outperform Dolaflexin's heterogeneous ADC population in preclinical models



• Histologic findings in Type II pneumocytes in animal models have not been seen with multiple other Dolasynthen ADCs directed towards other targets (data on file)

Efficacy



Figure 6: Waterfall Plot of Evaluable Patients Regardless of NaPi2b Expression

	All Patients All DLs	Ovarian Cancer ≥28 mg/m²
Patients, N	30 ^e	13 ^e
ORR, n (%)	5 (17%)	4 (31%)
SD, n (%)	19 (63%)	7 (54%)
DCR, n (%)	24 (80%)	11 (85%)
Median DOR, months	7.9	7.9

Table 3: Confirmed Best Overall Response of Evaluable Patients Regardless of NaPi2b Expression

CONCLUSIONS

• XMT-1592 is a NaPi2b-directed Dolasynthen ADC evaluated in a Phase 1 dose escalation trial in patients with platinum-resistant OC and non-squamous NSCLC



METHODS

XMT-1592 Phase 1 Dose Escalation Trial Design

- Enrolled patients with OC with histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancers; non-squamous NSCLC
- Measurable disease by RECIST 1.1
- ECOG performance status 0 or 1
- Available archival tumor tissue blocks, or freshly cut tissue slides for retrospective NaPi2b testing
- Dosing: XMT-1592 administered IV every 3 or 4 weeks
- Primary objectives: MTD or RP2D; safety and tolerability
- Escalation design: Modified version of the Simon accelerated titration design



- Platform-associated off-target toxicity with XMT-1592 appeared to be reduced relative to first-generation NaPi2b-directed ADCs. Fatigue, nausea, thrombocytopenia, and AST elevation occurred at a lower frequency and severity with XMT-1592 as compared to XMT-1536. No treatment-related bleeding events were reported with XMT-1592
- Pneumonitis was the most common TRAE with XMT-1592 and is believed to be an on-target toxicity due to NaPi2b expression in Type II pneumocytes. Histologic findings in Type II pneumocytes in animal models have not been seen with multiple other Dolasynthen ADCs directed towards other targets
- Responses were observed with XMT-1592 treatment in heavily pretreated patients, including one CR. In evaluable OC patients regardless of NaPi2b expression treated with 28 mg/m² or 56 mg/m², ORR was 31% with median DOR of 7.9 months
- Development of XMT-1592 was discontinued by the sponsor before completing the Phase 1 dose escalation due to portfolio reprioritization considerations

ACKNOWLEDGMENTS

- We would like to thank the patients, their families, and the site staff for making this study possible.
- This study is sponsored by Mersana Therapeutics, Inc.
- Editorial support for this poster was provided by Bio Connections LLC.

REFERENCES

- 1. Kiyamova R, et al. Exp Oncol. 2011;33(3):157_161.
- 2. Richardson D, et al. *Gynecol Oncol* Rep. 2022;44(2):S16-S17.
- 3. Banjeree S, et al. Ann Oncol. 2018;29(4):917_923.
- 4. Fessler S, et al. Can Res. 2020;80(suppl 16):2894.

ADDITIONAL INFORMATION

Scan the Quick Response (QR) code for downloadable PDF copies of this poster and author disclosures. PDF copies of this poster obtained through the QR code are for personal use only and may not be reproduced without permission.



Presented at the 2024 European Society of Gyneoclogical Oncology Annual Meeting, Barcelona, Spain, Mar 7-10, 2024

^a IHC labeling intensity: 1+ = weak; 2+ = moderate; 3+ = strong. ^b Adenocarcinoma. ^c Based on two independent studies. ^d Data cut: May 31, 2023 (UPLIFT: Phase 2 trial). ^e Evaluable patients; excludes one patient at 56 mg/m² who was non-evaluable by RECIST due to withdrawal of consent before first scan.

ADC, antibody-drug conjugate; AF-HPA, Auristatin F hydroxypropyl amide; AST, aspartate aminotransferase; CR, complete response; DAR, drug-to-antibody ratio; DCR, disease control rate; DL, dose level; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; Fcy, fragment crystallizable gamma receptor; G, grade; IHC, immunohistochemistry; ILD, interstitial lung disease; IV, intravenous; MTD, maximum tolerated dose; NaPi2b, sodium-dependent phosphate transporter 2b; NSCLC, non-small cell lung cancer; OC, ovarian cancer; ORR, objective response rate; PARP, poly-ADP ribose polymerase; PDX, patient-derived xenograft; PK, pharmacokinetics; gw, every week; RECIST, Response Evaluation Criteria in Solid Tumors; RP2D, recommended phase 2 dose; SD, stable disease; SEM, standard error of mean; TRAE, treatment-related adverse event; UV, ultraviolet.

